Estados Unidos · Plataformas y datos · Briefing.com

Vaxcyte Surges as OPUS-1 Phase 3 Results Strengthen VAX-31 Regulatory Path (PCVX)

Publicado por Briefing.com · Estados Unidos hace 14 d

Vaxcyte (PCVX) is soaring today after announcing topline results from the pivotal Phase 3 OPUS-1 trial evaluating VAX-31. VAX-31 is PCVX's investigational 31-valent pneumococcal…

Leer el artículo completo en Briefing.com Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.briefing.com)

Vaxcyte Surges as OPUS-1 Phase 3 Results Strengthen VAX-31 Regulatory Path (PCVX)

También te puede interesar

eToro Group (NASDAQ:ETOR) Sets New 52-Week Low on Analyst Downgrade

Better Retail Stock for 2026: GameStop vs. MercadoLibre

Cleveland-Cliffs projects $715M Q4 adjusted EBITDA and outlines path to more than $4B in 2027

One of this year’s most important relationships in global financial markets is falling apart

Anthropic is AI trade's last big hope for a major IPO this year

Cadence Design Systems stock may move 6.2% on earnings

Vaxcyte Surges as OPUS-1 Phase 3 Results Strengthen VAX-31 Regulatory Path (PCVX)

Compartir

También te puede interesar

eToro Group (NASDAQ:ETOR) Sets New 52-Week Low on Analyst Downgrade

Better Retail Stock for 2026: GameStop vs. MercadoLibre

Cleveland-Cliffs projects $715M Q4 adjusted EBITDA and outlines path to more than $4B in 2027

One of this year’s most important relationships in global financial markets is falling apart

Anthropic is AI trade's last big hope for a major IPO this year

Cadence Design Systems stock may move 6.2% on earnings